Main Article Content


: Background: Diabetes is represented as one of the most common and fastest prevalences in the world that expected to effect 693 million during 2045.

Objective: Our study aimed to assess the role of a genetic factor in patients who have diabetes.

Patients and methods We collected our data utilizing all relevant clinical and demographic parameters associated with different hospitals in Iraq, spanning from 16th June 2022 to 25th April 2023. Our research centred around patients of both genders, ranging between the ages of 23 and 50.  In order to develop the methodology, patient data was grouped based on the correlation between gene type and diabetes type, as well as specific SNP markers associated with each gene. Additionally, we analysed the impact of risk factors on patients in both observed and predicted status, including total cholesterol, LDL cholesterol, HDL cholesterol, and triglycerides. Furthermore, we explored the current correlation with genetic factors in diabetes patients. The SPSS program analysed our results, and we used Classify modelling, Linear regression model, nearest neighbor model, decision tree regression, and Q-Q figure plotting to predict the future impact of genetic factors and determine which gene led to high rates of diabetes among patients.

Results and discussion of the findings show that the percentage of cases with the AFF3 gene was high at 45%, whereas the ENPP7 gene was found in 27% of cases. Patients with high cholesterol levels had a total cholesterol level of 204.8 (mg/dL) and a low level of 175.10 (mg/dL). Similarly, patients with high triglyceride levels had a level of 197

(mg/dL) and a low level of 160.2 (mg/dL). Additionally, patients with low HDL cholesterol levels had 139.02 (mg/dL) and those with high levels had 144 (mg/dL), while patients with low LDL cholesterol levels had 135 (mg/dL) and those with high levels had 157 (mg/dL). Among these, the nearest neighbor model proved the most accurate, revealing that LDL cholesterol has the least importance, while HDL cholesterol holds the most significance.

Conclusions Our finding showed a linear correlation between the AFF3 gene and diabetes prevalence, with our predictive analysis revealing a negative effect of the AFF3 gene type on patients with diabetes.



Genetic factor; HDL, LDL, Total Cholesterol; Triglycerides; and Diabetes.

Article Details

How to Cite
Khaleel Ibrahim Ismael, Mustafa Faeq Kazem Hussein, & Abbas AbdulWahhab Jumaah Al-Salihi. (2023). The Effect of Genetics on The Prevalence of Diabetes in Patients. Central Asian Journal of Medical and Natural Science, 1-13. Retrieved from


  1. 1. Cho NH et al. IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045. Diabetes Res. Clin. Pract 138, 271–281, 2018.02.023 (2018).
  2. 2. Morrish NJ et al. Mortality and causes of death in the WHO multinational study of vascular disease in diabetes. Diabetologia 44, S14, doi:10.1007/PL00002934 (2001).
  3. 3. da Rocha Fernandes J et al. IDF Diabetes Atlas estimates of 2014 global health expenditures on diabetes. Diabetes Res. Clin. Pract 117, 48–54, .2016.04.016 (2016).
  4. 4. American Diabetes Association. Economic costs of diabetes in the US in 2017. Diabetes Care, dci180007 (2018).
  5. 5. Liyanage T et al. Worldwide access to treatment for end-stage kidney disease: A systematic review. Lancet 385, 1975–1982, doi:10.1016/S0140-6736 (14)61601-9 (2015). [PubMed: 25777665]
  6. 6. Brownlee M Biochemistry and molecular cell biology of diabetic complications. Nature 414, 813 820, doi:10.1038/414813a (2001).
  7. 7. American Diabetes Association. Classification and diagnosis of diabetes: Standards of medical care in diabetes. Diabetes Care 41, S13–S27, doi:10.2337/dc18-S002 (2018).
  8. 8. Udler MS et al. Type 2 diabetes genetic loci informed by multi-trait associations point to disease mechanisms and subtypes: A soft clustering analysis. PLoS Med 15, e1002654, doi:10.1371 journal. pmed.1002654 (2018).
  9. 9. Ahlqvist E et al. Novel subgroups of adult-onset diabetes and their association with outcomes: a data-driven cluster analysis of six variables. Lancet Diabetes Endocrinol 6, 361–369, doi:10.1016 S2213-8587 (18)30051-2 (2018).
  10. 10. Nathan DM et al. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N. Engl. J. Med 329, 977–986, doi:10.1056/nejm199309303291401 (1993).
  11. 11. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 352, 837–853 (1998).
  12. 12. Nathan DM et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N. Engl. J. Med 353, 2643–2653, doi:10.1056/NEJMoa052187 (2005). [PubMed: 16371630]
  13. 13. Prospective UK Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ (Clinical research ed.) 317, 703–713 (1998).
  14. 14. Lewis EJ, Hunsicker LG, Bain RP & Rohde RD the effect of angiotensin-convertingenzyme inhibition on diabetic nephropathy. N. Engl. J. Med 329, 1456–1462, doi:10.1056/ nejm199311113292004 (1993).
  15. 15. Brenner BM et al. Effects of Losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N. Engl. J. Med 345, 861–869, doi:10.1056/NEJMoa011161 (2001).
  16. 16. Zelniker TA et al. Comparison of the Effects of Glucagon-like peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus. Circulation 139, 2022–2031.118.038868 (2019).
  17. 17. Mahaffey Kenneth W et al. Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups. Circulation 140, 739–750, doi:10.1161/CIRCULATIONAHA.119.042007 (2019).
  18. 18. Perkovic V et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N. Engl. J. Med 380, 2295–2306 (2019).
  19. 19. Santer R et al. Molecular Analysis of the SGLT2 Gene in Patients with Renal Glucosuria. J. Am. Soc. Nephrol 14, 2873–2882, doi:10.1097/01. Asn.0000092790. 89332.D2 (2003).
  20. 20. Kim JJ, Hwang BH, Choi IJ, Choo EH, Lim S, Kim JK, Koh YS, Kim DB, Jang SW, Cho EJ, et al. Impact of diabetes duration on the extent and severity of coronary atheroma burden and long-term clinical outcome in asymptomatic type 2 diabetic patients: evaluation by Coronary CT angiography. Eur Heart J Cardiovasc Imaging. 2015;16 (10):1065–73.
  21. 21. Rana JS, Dunning A, Achenbach S, Al-Mallah M, Budof MJ, Cademartiri F, Callister TQ, Chang HJ, Cheng VY, Chinnaiyan K, et al. Diferences in prevalence, extent, severity, and prognosis of coronary artery disease among patients with and without diabetes undergoing coronary computed tomography angiography: results from 10,110 individuals from the CONFIRM (COronary CT Angiography EvaluatioN for Clinical Outcomes): an InteRnational Multicenter Registry. Diabetes Care. 2012;35 (8):1787–94.
  22. 22. Ozcan C, Deleskog A, Schjerning Olsen AM, Nordahl Christensen H, Lock Hansen M, Hilmar Gislason G. Coronary artery disease severity and long-term cardiovascular risk in patients with myocardial infarction: a Danish nationwide register-based cohort study. Eur Heart J Cardiovasc Pharmacother. 2018;4 (1):25–35.
  23. 23. Huo Y, Lee SW, Sawhney JP, Kim HS, Krittayaphong R, Nhan VT, AlonsoGarcia A, Han YL, Ge J, Chin CT, et al. Rationale, design, and baseline characteristics of the EPICOR Asia Study (Long-term follow-up of antithrombotic management patterns In Acute CORonary Syndrome patients in Asia). Clin Cardiol. 2015;38 (9):511–9.
  24. 24. van Leeuwen EM, Kanterakis A, Deelen P, Kattenberg MV, Slagboom PE, de Bakker PI, Wijmenga C, Swertz MA, Boomsma DI, van Duijn CM, et al. Population-specific genotype imputations using minimac or IMPUTE2. Nat Protoc. 2015;10 (9):1285–96.
  25. 25. Abecasis GR, Altshuler D, Auton A, Brooks LD, Durbin RM, Gibbs RA, Hurles ME, McVean GA. A map of human genome variation from population-scale sequencing. Nature. 2010;467 (7319):1061–73.